Scil Proteins, a German private biotech company specialising in the research, development and production of recombinant proteins, has appointed Ulrich Haupts as its new chief scientific officer. As of 1 October, he will replace Arnd Steuernagel.
Haupts was previously director of protein optimisation at Bayer Healthcare, a position he has held for the last three years. Prior to that, he spent seven years at Direvo Biotech (which was subsequently acquired by Bayer Schering Pharma in 2008) as department head of assay development and later, as vp of r&d biopharmaceuticals.
Dr Haupts also worked for three years at SmithKline Beecham UK in the New Assay Technology group.
Scil Proteins appoints chief scientific officer
Ulrich Haupts joins the biotech firm from Bayer Healthcare
You may also like
Research & Development
Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells
Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies